Sage lays off 55% of R&D workforce and refocuses pipeline
After a series of mid-stage clinical trial failures, Sage Therapeutics has announced that it will jettison 165 employees, which totals 55% of its R&D team and 33% of its entire workforce. As per the 17 October press release,
Sage Therapeutics Cuts Workforce by 33% in Reorganization, Focuses on ZURZUVAE Launch and Pipeline
Several executives will depart as part of the changes, including Anne Marie Cook, Kimi Iguchi, Matt Lasmanis, Heinrich Schlieker, and Amy Schacterle. Chris Benecchi will be looking to take up the reins as Chief Operating Officer, overseeing several departments, while Greg Shiferman and Vanessa Procter will assume expanded leadership roles.
Sage Therapeutics Cutting Workforce by 33% -- Update
Sage on Thursday said the reorganization will affect more than 165 employees, representing about 33% of the Cambridge, Mass., company's total workforce and more than half of its research-and-development staff.
Sage Therapeutics to lay off more than 165 employees
Sage Therapeutics said on Thursday it will lay off more than 165 employees, or about 33% of the company's total workforce, as part of a reorganization plan. The drugmaker plans to prioritize the launch of postpartum depression treatment Zurzuvae,
Sage Therapeutics to lay off one-third staff under reorganization
Sage Therapeutics (NASDAQ:SAGE) announced a reorganization, including a workforce reduction of about 33%, to support the ongoing launch of ZURZUVAE for postpartum depression and to focus on pipeline development ahead of a clinical readout for dalzanemdor in Huntington’s Disease expected later this year.
Sage Therapeutics’ stock falls 4.7% as biotech unveils plan to cut 33% of workforce
Sage Therapeutics Inc.’s stock slid 4.7% Thursday, after the biotech said it’s cutting about 33% of its workforce as part of ...
Sage Therapeutics Announces Strategic Reorganization to Prioritize ZURZUVAE® Commercialization and Focus its Development Portfolio
Sage Therapeutics, Inc. (Nasdaq: SAGE), today announced a strategic reorganization of its business operations to support the ongoing launch of ZURZUVAE in postpartum depression and focus pipeline ...
STAT9d
Biogen turns to telehealth company to boost its postpartum depression drug
Talkiatry partnership resembles efforts by pharma companies like Eli Lilly and Pfizer to team up with telehealth companies.
pharmaphorum9d
Biogen, Talkiatry team up on postpartum depression
The FDA approved Zurzuvae as the first oral therapy for post-partum depression (PPD) in August 2023, although, the agency ...
Business Wire21d
Sage Therapeutics Announces Discontinuation of the Collaboration with Biogen on the SAGE-324 Program
Sage and Biogen will continue to partner on ZURZUVAE® (zuranolone), the first and only FDA-approved oral treatment for women with postpartum depression (PPD) and will continue to work on their ...
Benzinga.com21d
Biogen Terminates Collaboration With Sage Therapeutics For Neurological Disorder Candidate
The companies will continue to collaborate on Zurzuvae, the FDA-approved treatment for postpartum depression. The companies recently announced negative results from the Phase 2 KINETIC 2 Study of ...
The American Journal of Managed Care28d
Dr Rachel Dalthorp Discusses the Difference Between Depression and Postpartum Depression
Rachel Dalthorp, MD, discusses how zuranolone (Zurzuvae) can improve postpartum depression when compared with previous treatment approaches. In this interview, Rachel Dalthorp, MD, executive ...